GeneOne Life Science, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 12,547.98 million compared to KRW 6,514.97 million a year ago. Net loss was KRW 7,904.28 million compared to KRW 5,501.3 million a year ago. Basic loss per share from continuing operations was KRW 102 compared to KRW 81.3333 a year ago. Diluted loss per share from continuing operations was KRW 102 compared to KRW 81.3333 a year ago. Basic loss per share was KRW 102 compared to KRW 122 a year ago.
For the nine months, sales was KRW 26,785.69 million compared to KRW 18,445.25 million a year ago. Net loss was KRW 23,499.64 million compared to KRW 13,615.32 million a year ago. Basic loss per share from continuing operations was KRW 303 compared to KRW 202 a year ago. Diluted loss per share from continuing operations was KRW 303 compared to KRW 202 a year ago. Basic loss per share was KRW 303 compared to KRW 303 a year ago.